 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Regeneron Pharmaceuticals
REGN
conference date: October 31, 2024 @ 5:30 AM Pacific Time
Regeneron Pharmaceuticals Boosted by COPD Data [March 25, 2024 at Seeking Alpha]
Regeneron Priced Right For Long-Term Investors [September 27, 2019 at Seeking Alpha]
Regeneron: A Buy On Dupixent And Pipeline [August 15, 2018 at Seeking Alpha]
Regeneron Unknown: Eylea Future Competition Effects [May 17, 2018]
Analyst Conference Notes by William P. Meyers |
|||
| 2024 | |||
| Regeneron Q1 2024 |
Regeneron Q2 2024 |
Regeneron Q3 2024 |
|
| May 2, 2024 | Aug. 1, 2024 | Oct. 31, 2024 | |
| 2023 | |||
| Regeneron Q1 2023 |
Regeneron Q2 2023 |
Regeneron Q3 2023 |
Regeneron Q4 2023 |
| May 4, 2023 | Aug. 3, 2023 | Nov. 2, 2023 | Feb. 2, 2024 |
| 2022 | |||
| Regeneron Q1 2022 |
missed | Regeneron Q3 2022 |
Regeneron Q4 2022 |
| May 4, 2022 | Aug. 3, 2022 | Nov. 3, 2022 | Feb. 3, 2023 |
| 2021 | |||
| Regeneron Q1 2021 |
Regeneron Q2 2021 |
Regeneron Q3 2021 |
Regeneron Q4 2021 |
| May 6, 2021 | Aug. 5, 2021 | Nov. 4, 2021 | Feb. 4, 2022 |
| 2020 | |||
| Regeneron Q1 2020 |
Regeneron Q2 2020 |
Regeneron Q3 2020 |
Regeneron Q4 2020 |
| May 5, 2020 | Aug. 5, 2020 | Nov. 5, 2020 | Feb. 5, 2021 |
| 2019 | |||
| Regeneron Q1 2019 |
Regeneron Q2 2019 |
Regeneron Q3 2019 |
Regeneron Q4 2019 |
| May 7, 2019 | August 6, 2019 | Nov. 5, 2019 | Feb. 6, 2019 |
2018 |
|||
May 3, 2018 |
August 8, 2018 |
Nov. 6, 2018 |
Feb. 6, 2019 |
2017 |
|||
May 4, 2017 |
August 3, 2017 |
Nov. 8, 2017 |
Feb. 8, 2018 |
2016 |
|||
05/05/2016 |
08/04/2016 |
11/04/2016 |
02/09/2017 |
2015 |
|||
05/07/2015 |
08/04/2015 |
11/04/2015 |
02/09/2016 |
2014 |
|||
05/08/2014 |
08/05/2014 |
11/04/2014 |
02/10/2015 |
2013 |
|||
not available |
|||
08/06/2013 |
11/05/2013 |
02/11/2014 |
|
Regeneron (REGN) is a biotechnology company currently providing Eylea for Wet Macular Degeneration, Arcalyst for Cryopyrin-Associated Periodic Syndromes (CAPS), and Zaltrap for metastatic colorectal cancer.
Regeneron web site
Regeneron investor relations page
Note that I owned Regeneron stock from June 24, 2014 to January 10, 2017
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BLUE |
| BMY |
| CLDX |
| CDTX |
| FATE |
| GILD |
| GLYC |
| INCY |
| ILMN |
| INO |
| IONS |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SANA |
| SYRS |
| TSVT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. These are my personal notes and serve as the basis of my Seeking Alpha articles.
Copyright 2024 William P. Meyers